Overview of Лопинавир
| Quick Facts | Description |
|---|---|
| Active ingredient | Lopinavir (with Ritonavir booster) |
| Form | Film-coated tablets, Oral solution |
| Pharmacological class | Antiretroviral Agent (Protease Inhibitor) |
| Common use | Management of HIV-1 infection |
| Origin | Synthetic Organic Compound |
Lopinavir: Pharmacological Class and Composition
Lopinavir (Лопинавир) is a synthetic anti-retroviral agent that belongs to the protease inhibitor (PI) pharmacological class, a designation clinically recognized across international guidelines. It is exclusively prescribed as a fixed-dose combination product for oral administration, always containing two active ingredients: Lopinavir itself and the necessary enhancer, Ritonavir (Ритонавир).
The inclusion of Ritonavir in a low dose is a key differentiating feature of this agent, as it acts as a pharmacokinetic enhancer or "booster," inhibiting the breakdown of Lopinavir by liver enzymes. This co-formulation strategy ensures high systemic exposure to the primary drug. The combination is recognized for its role in global therapy. Available forms, such as film-coated tablets and a specific oral solution, highlight its formulation designed to serve diverse patient groups, including pediatric patients.
Principle of Action and Main Purpose
The primary purpose of the Lopinavir/Ritonavir combination is to achieve and sustain viral suppression by significantly reducing the amount of Human Immunodeficiency Virus (HIV) in the body. The fundamental action involves the selective inhibition of the HIV protease enzyme. This unique enzymatic target is critical because the enzyme is required by the virus to cleave its large protein precursors into the functional components necessary to construct mature, infectious viral particles.
By actively blocking this enzymatic process, the medication prevents the virus from maturing and spreading effectively to other cells. This potent antiviral activity leads to a profound reduction in the patient's viral load, which is the key measure of therapeutic success. This capacity for robust viral control has positioned Lopinavir/Ritonavir as an important option for patients undergoing antiretroviral therapy, offering a verified path to managing the HIV infection and preventing the progression to Acquired Immunodeficiency Syndrome (AIDS).
